The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants (Q34497909)

2 August 2017

title

The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants (English)

1 reference

2 August 2017

1 reference

Golo Kronenberg

3

0 references

Mazda Adli

series ordinal

4

object named as

Mazda Adli

1 reference

2 August 2017

Stephan Köhler

1

1 reference

2 August 2017

Katharina Cierpinsky

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

13 October 2015

1 reference

Journal of Psychopharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

30

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

13-22

1 reference

Modulation of dopamine release by striatal 5-HT2C receptors

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Comment on: 'antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonin receptor antagonists for highly emetogenic chemotherapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The CRF system, stress, depression and anxiety-insights from human genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The effect of vilazodone on sexual function during the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Rediscovering trazodone for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

5-HT2C Receptor Agonists and the Control of Appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The 5-HT7 receptor and disorders of the nervous system: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Dopamine and serotonin: influences on male sexual behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vilazodone for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Triptans for the management of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A decade of antidepressant development: the SSRIs and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Depressed new neurons--adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

[Individualized treatment with antidepressants].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Of mice and men: modelling post-stroke depression experimentally

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Levomilnacipran: a newly approved drug for treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Structure and function of serotonin G protein-coupled receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonergic mechanisms as targets for existing and novel antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

5-HT6 Receptor Memory and Amnesia: Behavioral Pharmacology – Learning and Memory Processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Modulating the serotonin system in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The 5‐HT7 receptor in learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The 5-HT1B receptor: a novel target for the pathophysiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Neuroreceptor imaging in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonin 1A receptors and sexual behavior in male rats: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Serotonergic drugs for depression and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

5-ht5A receptors as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

The Roles of Neurotrophic Factor and Wnt Signaling in Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

A proposal for an updated neuropsychopharmacological nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881115609072

21 January 2018

Identifiers

DOI

10.1177/0269881115609072

1 reference

2 August 2017

1 reference